MGO One Seven LLC Buys 5,009 Shares of Becton, Dickinson and Company (NYSE:BDX)

MGO One Seven LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 118.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,228 shares of the medical instruments supplier's stock after purchasing an additional 5,009 shares during the quarter. MGO One Seven LLC's holdings in Becton, Dickinson and Company were worth $2,094,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in BDX. Norges Bank bought a new position in Becton, Dickinson and Company during the 4th quarter valued at about $735,523,000. First Eagle Investment Management LLC grew its holdings in Becton, Dickinson and Company by 31.4% during the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock valued at $1,004,132,000 after buying an additional 1,057,879 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Becton, Dickinson and Company by 15.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after buying an additional 810,345 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $181,279,000. Finally, Nordea Investment Management AB raised its holdings in Becton, Dickinson and Company by 31.0% during the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier's stock valued at $647,082,000 after buying an additional 673,568 shares during the period. Institutional investors own 86.97% of the company's stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares of the company's stock, valued at $964,107.36. This trade represents a 8.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey William Henderson acquired 1,500 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was purchased at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the acquisition, the director now directly owns 8,015 shares of the company's stock, valued at $1,872,464.30. The trade was a 23.02 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 3,578 shares of company stock valued at $795,986. Company insiders own 0.36% of the company's stock.

Analysts Set New Price Targets

BDX has been the topic of a number of recent research reports. StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 2nd. Piper Sandler reduced their price objective on Becton, Dickinson and Company from $280.00 to $260.00 and set an "overweight" rating for the company in a research note on Wednesday, April 23rd. Finally, Barclays decreased their price objective on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a report on Monday, April 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company has an average rating of "Buy" and a consensus price target of $272.86.

Becton, Dickinson and Company Stock Performance

BDX traded up $0.02 during trading on Monday, reaching $205.10. The company's stock had a trading volume of 1,400,220 shares, compared to its average volume of 1,735,825. Becton, Dickinson and Company has a 52-week low of $193.03 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The company has a market capitalization of $58.89 billion, a price-to-earnings ratio of 34.07, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company's fifty day moving average price is $218.51 and its 200-day moving average price is $227.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were given a dividend of $1.04 per share. The ex-dividend date was Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 2.03%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.